BACKGROUND: Recent advances in @entity356 chemotherapy have made macroscopic complete resection possible in some @entity1 with stage IV disease. METHODS: We retrospectively investigated the efficacy of multimodal therapy with combined @entity1205 , @entity900 , and @entity11730 (DCS) and conversion gastrectomy in 57 @entity1 with @entity5 . RESULTS: Of the 57 @entity1 , 15 @entity1 were categorized into potentially resectable case, which is defined as @entity1 with single incurable factor including the upper abdominal para-aortic lymph node @entity3 (16a2b1 PAN @entity3 ) or fewer than three peripheral liver metastases. The other 42 were categorized as initially unresectable. All of @entity1 underwent DCS therapy, and then 34 @entity1 underwent conversion gastrectomy. The 3-year @entity1349 ( @entity1349 ) rate among the @entity1 who underwent conversion gastrectomy was 50.1% with MST of 29.9 months. They had significantly longer @entity1349 than @entity1 who underwent DCS therapy alone (p  <  0.01). Univariate analysis among the patents with conversion gastrectomy identified 16a2b1PAN @entity3 , peritoneal @entity3 , potential resectable case, R0 resection as significant prognostic factors. A 3-year @entity1349 in potential resectable cases was 92.9%. Multivariate analysis identified potential resectability as the only independent prognostic factor contributing to @entity1349 (HR 0.133, 95%CI 0.024-0. 744, p  =  0.021). In contrast, clinical response was selected as the only independent prognostic factor in the subgroup of initially unresectable cases (HR 0.354, 95%CI 0.151-0.783, p  =  0.021). CONCLUSION: @entity1 with potentially resectable disease had a remarkably good prognosis among @entity5 @entity1 , and might be ideal candidates for conversion gastrectomy following DCS therapy.

Efficacy of conversion gastrectomy following @entity1205 , XXXX , and @entity11730 therapy in potentially resectable @entity5 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity11730 :: ('5707', 'Gene') :: ['S-1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage IV gastric cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
